These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase. Pardin C; Roy I; Lubell WD; Keillor JW Chem Biol Drug Des; 2008 Sep; 72(3):189-96. PubMed ID: 18715232 [TBL] [Abstract][Full Text] [Related]
4. Functional significance of five noncanonical Ca2+-binding sites of human transglutaminase 2 characterized by site-directed mutagenesis. Király R; Csosz E; Kurtán T; Antus S; Szigeti K; Simon-Vecsei Z; Korponay-Szabó IR; Keresztessy Z; Fésüs L FEBS J; 2009 Dec; 276(23):7083-96. PubMed ID: 19878304 [TBL] [Abstract][Full Text] [Related]
5. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor. Case A; Stein RL Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993 [TBL] [Abstract][Full Text] [Related]
6. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. Schaertl S; Prime M; Wityak J; Dominguez C; Munoz-Sanjuan I; Pacifici RE; Courtney S; Scheel A; Macdonald D J Biomol Screen; 2010 Jun; 15(5):478-87. PubMed ID: 20395409 [TBL] [Abstract][Full Text] [Related]
7. Fluorescent probes of tissue transglutaminase reveal its association with arterial stiffening. Chabot N; Moreau S; Mulani A; Moreau P; Keillor JW Chem Biol; 2010 Oct; 17(10):1143-50. PubMed ID: 21035737 [TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 2 undergoes a large conformational change upon activation. Pinkas DM; Strop P; Brunger AT; Khosla C PLoS Biol; 2007 Dec; 5(12):e327. PubMed ID: 18092889 [TBL] [Abstract][Full Text] [Related]
9. A sensitive fluorometric assay for tissue transglutaminase. Jeitner TM; Fuchsbauer HL; Blass JP; Cooper AJ Anal Biochem; 2001 May; 292(2):198-206. PubMed ID: 11355851 [TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of transglutaminase 2 by PKA at Ser216 creates 14-3-3 binding sites. Mishra S; Murphy LJ Biochem Biophys Res Commun; 2006 Sep; 347(4):1166-70. PubMed ID: 16870138 [TBL] [Abstract][Full Text] [Related]
11. Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions. Badarau E; Wang Z; Rathbone DL; Costanzi A; Thibault T; Murdoch CE; El Alaoui S; Bartkeviciute M; Griffin M Chem Biol; 2015 Oct; 22(10):1347-61. PubMed ID: 26456735 [TBL] [Abstract][Full Text] [Related]
12. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival. Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875 [TBL] [Abstract][Full Text] [Related]
13. Substrate preference of transglutaminase 2 revealed by logistic regression analysis and intrinsic disorder examination. Csosz E; Bagossi P; Nagy Z; Dosztanyi Z; Simon I; Fesus L J Mol Biol; 2008 Nov; 383(2):390-402. PubMed ID: 18761350 [TBL] [Abstract][Full Text] [Related]
14. Reaction profiling of a set of acrylamide-based human tissue transglutaminase inhibitors. Jasim MH; Rathbone DL J Mol Graph Model; 2018 Jan; 79():157-165. PubMed ID: 29179065 [TBL] [Abstract][Full Text] [Related]
15. Mechanism of allosteric regulation of transglutaminase 2 by GTP. Begg GE; Carrington L; Stokes PH; Matthews JM; Wouters MA; Husain A; Lorand L; Iismaa SE; Graham RM Proc Natl Acad Sci U S A; 2006 Dec; 103(52):19683-8. PubMed ID: 17179049 [TBL] [Abstract][Full Text] [Related]
16. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729 [TBL] [Abstract][Full Text] [Related]
17. Development of carbon-11 labeled acryl amides for selective PET imaging of active tissue transglutaminase. van der Wildt B; Wilhelmus MM; Bijkerk J; Haveman LY; Kooijman EJ; Schuit RC; Bol JG; Jongenelen CA; Lammertsma AA; Drukarch B; Windhorst AD Nucl Med Biol; 2016 Apr; 43(4):232-42. PubMed ID: 27067043 [TBL] [Abstract][Full Text] [Related]
18. Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2. Klöck C; Jin X; Choi K; Khosla C; Madrid PB; Spencer A; Raimundo BC; Boardman P; Lanza G; Griffin JH Bioorg Med Chem Lett; 2011 May; 21(9):2692-6. PubMed ID: 21215619 [TBL] [Abstract][Full Text] [Related]
19. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors. Song M; Hwang H; Im CY; Kim SY J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456 [TBL] [Abstract][Full Text] [Related]
20. Mechanism for the inhibition of transglutaminase 2 by cystamine. Jeitner TM; Delikatny EJ; Ahlqvist J; Capper H; Cooper AJ Biochem Pharmacol; 2005 Mar; 69(6):961-70. PubMed ID: 15748707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]